Thursday, February 1, 2007 Friday, February 2, 2007 Saturday, February 3, 2007
THURSDAY, FEBRUARY 1, 2007
Session I - Basic Biology and Preclinical Data – Part 1
8:00 AM – 12:05 PM
   •   Opening Remarks and Overview of Current State of the Field Lee Ellis, MD
   •   Inhibiting the Akt signaling pathway in Tumor Angiogenesis Laura Benjamin, PhD
   •   Lymphangiogenesis Factors and Lymphatic Metastasis Yihai Cao, MD, PhD
   •   VEGF and PDGF Inhibitor Actions on Tumor Blood Vessels Donald McDonald, MD, PhD
   •   Microenvironmental Influences on Tumor Angiogenesis Gabriele Bergers, PhD
   •   Studying Vascular Morphology Using the Zebrafish Brant Weinstein, PhD
   •   Effects of Radiation and Chemotherapy on HIF-1 Expression: 
         Strategies to Sensitize Tumor Vasculature		 Mark Dewhirst, DVM, PhD
   •   Molecular and Cellular Biomarkers for Targeted Anti-Angiogenic
         Drugs and Metronomic Chemotherapy		 Robert Kerbel, PhD
Session II - Basic Biology and Preclinical Data – Part 2

1:00 PM – 4:00 PM
   •   Integrating Role of Delta 4:  Notch Signaling in Tumor Angiogenesis  Adrian Harris, MBChB, MA, DPhil, FRCP
   •   Contribution of Hematopoietic Cells to Tumor Invasion Shahin Rafii, MD
 
  New & Emerging Targets:
   •   Chemokines Joost Oppenheim, MD
   •   Development of Oligosaccharides as Anti-Angiogenic Agents Gordon Jayson, FRCP, PhD
   •   Notch  Jan Kitajewski, MD
   •   α4β1 Integrin  Judy Varner, PhD
 
  Keynote Lecture:
   •   Novel Anti-Angiogenic Opportunities: Inhibiting PIGF Peter Carmeliet, MD, PhD
 
Wine & Cheese Poster Session 4:00 pm – 5:30 pm
Back to Top

FRIDAY, FEBRUARY 2, 2007

Session III:  Early Drug Development/Clinical Trial Results
8:00 AM – 12:05 PM
   •   Early Drug Development  
      -   BIBF1120 Gordon Rustin, MD, MSc, FRCP
      -   Bevacizumab/Everolimus Herbert Hurwitz, MD
      -   ATN224 Adrian Harris, MBChB, MA, DPhil, FRCP
   •   Phase I Trial of CT-322/Angiocept Anthony Tolcher, MD
   •   Lessons Learned from Early Drug Development Lee Rosen, MD
   •   Combinations of Anti-Angiogenic Therapies S. Gail Eckhardt, MD
   •   Development of Angiogenesis Inhibitors in Melanoma Keith T. Flaherty, MD
   •   Anti-Angiogenic Therapy for the Treatment of Myelodysplastic Alan List, MD
   •   Overview of Vascular Targeting Agents Gordon Rustin, MD, MSc, FRCP
 

Session IV:  Clinical Trial Result

1:00 PM – 4:00 PM
   •   Development of Anti-Angiogenic Agents for Ovarian Cancer Gordon Jayson, FRCP, PhD
   •   Anti-Angiogenic Therapy for the Treatment of CNS Malignancies David Reardon, MD
   •   Micro-Ultrasound: A New Approach for Functional and
       Molecular Imaging of Angiogenesis		 Stuart Foster, PhD
   •   Clinical Progress in Anti-Angiogenic Therapy for the Treatment 
        of Ocular Disease		 Marty Friedlander, MD, PhD
   •   Anti-Angiogenic Therapy for the Treatment of Neuroendocrine Tumors James Yao, MD
 
Social Reception 6:00 PM – 7:30 PM
Back to Top

SATURDAY, FEBRUARY 3, 2007

Session V:  Clinical Trial Results
8:00 AM – 12:05 PM
   •   Anti-Angiogenic Therapy for the Treatment of Pancreatic Cancer Hedy Lee Kindler, MD
   •   Targeted Anti-Angiogenic Therapy for Advanced RCC: Where Do We Go 
         from Here?		 Brian Rini, MD
   •   Will Blood Tell the Tale? Anti-Angiogenic Therapy in Breast Cancer George Sledge, Jr, MD
   •   Angiogenesis in Lung Cancer: The Bases are Loaded But Will it be a
         Home Run? 		 Frances Shepherd, MD, FRCP(C)
   •   Anti-Angiogenic Therapy for the Treatment of Colon Cancer Paulo Hoff, MD
Back to Top
Contact Us   |   Powered by SciMedMedia